Healthcare AI News – June 4, 2025 – HIStalk
- Artificial intelligence continues to make inroads in healthcare, with new funding, tools, and implementations emerging.
- The Food and Drug Administration (FDA) has launched Elsa, a generative AI tool for automating tasks such as reading, writing, and summarization for its employees. The FDA is...
- Major healthcare players are investing heavily in technology.
Amperos Health secures $4.2M in seed funding too launch Amanda, its AI-powered denial management tool, marking a notable step forward in healthcare RCM. the FDA unveils Elsa, a generative AI tool designed to automate internal tasks and streamline processes. Moreover, CVS Health will invest $20 billion in tech upgrades embracing AI for pharmacy applications. Mount Sinai develops AI for insulin dosing post-surgery, indicating AI’s growing role in clinical support. AssistIQ and SoundHound also have notable developments. These advancements highlight the rapid integration of artificial intelligence within healthcare. While the sector shows optimism, challenges related to overreliance and robust governance of healthcare AI still exist. Stay informed with News Directory 3 for more on this and related AI news.Discover what’s next as innovation accelerates in patient care and administrative processes.
AI Advances in Healthcare: Funding, FDA Initiatives, and Clinical Tools
Updated June 05, 2025
Artificial intelligence continues to make inroads in healthcare, with new funding, tools, and implementations emerging. Amperos Health, an RCM AI company, recently announced $4.2 million in seed funding and the launch of Amanda, an AI tool designed to automate denial management and collections for healthcare providers.
Government agencies are also exploring AI. The Food and Drug Administration (FDA) has launched Elsa, a generative AI tool for automating tasks such as reading, writing, and summarization for its employees. The FDA is also developing AI for medical device reviews within its center for devices and Radiological Health, currently in beta testing.
Major healthcare players are investing heavily in technology. CVS Health plans to spend $20 billion over the next decade on technology upgrades, including AI applications in its patient-facing pharmacy phone system. Tilak Mandadi, CVS Health’s Chief Experience and Technology Officer, emphasized that AI will not be used for clinical decision-making or denials.
Elsewhere, AssistIQ, which develops AI-powered supply chain and management software, announced $11.5 million in funding. northwell Health in New York has already implemented AssistIQ’s AIQ capture solution.
Allina Health in Minnesota has implemented SoundHound AI’s agentic AI call center technology, built on the Amelia AI platform acquired last August.
Research institutions are also developing AI solutions. Mount Sinai researchers have created a machine learning model,GLUCOSE,to assist with insulin dosing for patients recovering from heart surgery in the ICU. The researchers emphasize that GLUCOSE is a clinical decision support tool, not a replacement for physicians.
A recent report from Wolters Kluwer Health indicates that while providers are optimistic about AI’s potential benefits for staffing and clinical processes, many are hesitant to fully adopt the technology. concerns include overreliance on AI and the lack of governance policies and training programs to ensure responsible AI use.
what’s next
As AI continues to evolve, its integration into healthcare is expected to expand, driving further innovation in patient care, administrative processes, and clinical decision-making. However, responsible implementation and governance will be crucial to address concerns and ensure patient safety.